Multiple Sclerosis Clinical Trial

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Summary

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants must have been diagnosed with relapsing MS

Participants must have one of the following

at least 1 documented relapse within the previous year, or
at least 2 documented relapse within the previous 2 years, or
at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.

Exclusion Criteria:

Have had a diagnosis of primary progressive MS
Have a history of another clinically significant neurological disease
Had a relapse of MS within 30 days prior to randomization.

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Study ID:

NCT06104683

Recruitment Status:

Withdrawn

Sponsor:

Loxo Oncology, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

University of South Florida
Tampa Florida, 33612, United States
Clinical Trial Network
Houston Texas, 77074, United States
Swedish Medical Center-501 E Hampden Ave
Seattle Washington, 98122, United States
Caribbean Center For Clinical Research Inc
Guaynabo , 969, Puerto Rico

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Study ID:

NCT06104683

Recruitment Status:

Withdrawn

Sponsor:


Loxo Oncology, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.